Tafamidis
Orphan DrugFDA Approved
Contents
Description
Tafamidis is a transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy. It works by stabilizing the tetrameric form of transthyretin protein, preventing its dissociation and subsequent amyloid formation. While specifically approved for ATTR amyloidosis, it represents a therapeutic approach for protein misfolding disorders.
Indications & Therapeutic Use
Transthyretin amyloid cardiomyopathy, transthyretin amyloid polyneuropathy
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Tafamidis — GNH India
30 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Vyndamax
61mgcapsuleAustralia
Vyndaqel
20mgcapsuleUSA
Vyndaquel
61mgcapsuleSwitzerland
Vyndaqel 61mg
61mgcapsuleTurkey
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Tafamidis
| Generic Name | Tafamidis |
| Brands | 1 brand available |
| Active Ingredient | Tafamidis meglumine |
| Drug Class | Transthyretin amyloid cardiomyopathy |
| Manufacturer | Pfizer |
| Dosage Forms | Oral capsule 20mg, 61mg |
| Medical Code | N07XX08 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT01994889 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes